



## **ASX ANNOUNCEMENT**

### **Lumos Withdraws Participation In Local Manufacturing Proposal**

**Melbourne, VIC. (08 August 2022)** - Lumos Diagnostics (ASX:LDX, “Lumos” or the “Company”) today announces that as part of its ongoing restructuring and rationalisation program, the Company has advised the Victorian State Government that it no longer intends to participate in the establishment of a Diagnostics Manufacturing Facility in Victoria.

In February 2022, Lumos announced that the Victorian State Government had proposed an intended package of support for a Rapid Antigen Test (RAT) manufacturing facility in Victoria to potentially be established in collaboration with Lumos. In conjunction with Chief Executive Officer Doug Ward, Lumos’ Board has determined that the Company is not currently in a position where it can commit to providing the capital investment and human resources required to support the establishment of such a facility within the intended timeframes. In light of this, the Company has advised the Victorian State Government that it cannot participate in the establishment of this facility at this time.

“Lumos is paying close attention to its operational priorities and investment commitments as evidenced by the recent announcement regarding the planned closure our Sarasota facility,” said Doug Ward, CEO of Lumos Diagnostics. “While we continue to see great potential for establishing a diagnostics capability in Victoria, at this time Lumos needs to focus on leveraging its existing assets rather than investing in new assets. Lumos is currently concentrating on securing regulatory clearances to drive commercial sales revenue from its portfolio of point-of-care diagnostics products, and on leveraging its reader technology and established development services and manufacturing capability in Carlsbad, to grow its Commercial Services business.”

***This announcement has been approved by the Lumos Disclosure Committee***

###

**About Lumos Diagnostics**

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com) or call +1 941-556-1850.

**Forward-Looking Statements**

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

**Media Contact:**

Matthew Wright – Australia  
Director, NWR Communications  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)  
+61 (0) 451 896 420

**Investor Contact:**

Matthijs Smith – Lumos Diagnostics  
[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)  
+61 3 9087 1598

**Company Registered Office:**

Lumos Diagnostics Holdings Ltd  
Level 4, 100 Albert Rd  
South Melbourne, VIC 3205  
+61 3 9087 1598